Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio, Inc. (PASG) will participate in investor conferences like TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference to discuss their clinical-stage genetic medicines for neurodegenerative diseases. A webcast will be available for investors on the company's website.
02/27/2024 - 07:00 AM
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference
Leerink Partners Global Biopharma Conference
A live webcast of the panel discussion will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com . A replay of the panel will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com .
For further information, please contact:
Investors:shenderson@passagebio.com
Passage Bio Media:mikebeyer@sambrown.com
When will Passage Bio participate in the TD Cowen 44th Annual Health Care Conference?
Passage Bio will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 10:30 a.m. ET in Boston, MA.
Where will Passage Bio participate in the Leerink Partners Global Biopharma Conference?
Passage Bio will participate in the Leerink Partners Global Biopharma Conference in Miami, FL for investor meetings on Wednesday, March 13, 2024.
Will there be a webcast available for investors?
Yes, a live webcast of the panel discussion will be available on Passage Bio's website at investors.passagebio.com, with a replay available for 30 days after the event.
PASG Rankings
#4610 Ranked by Stock Gains
PASG Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About PASG
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
